tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Ashwani Verma, 37 are a BUY (71.15%), 12 are a HOLD (23.08%), 3 are a SELL (5.77%).
Analyst Ashwani Verma, currently employed at UBS, carries an average stock price target met ratio of 65.83% that have a potential upside of 24.72% achieved within 164 days.
Ashwani Verma’s has documented 104 price targets and ratings displayed on 14 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on NBIX, Neurocrine Biosciences at 08-Jan-2025.
Analyst best performing recommendations are on RANI (RANI THERAPEUTICS HOLDINGS).
The best stock recommendation documented was for RANI (RANI THERAPEUTICS HOLDINGS) at 11/15/2023. The price target of $4 was fulfilled within 146 days with a profit of $2.01 (101.01%) receiving and performance score of 6.92.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$100
$-26.2 (-20.76%)
$100
8 days ago
(13-Jan-2025)
24/25 (96%)
$-27.71 (-21.70%)
165
Buy
$89
$-37.2 (-29.48%)
$81
2 months 17 days ago
(04-Nov-2024)
9/9 (100%)
$2.02 (2.32%)
43
Buy
$95
$-31.2 (-24.72%)
$80
3 months 10 days ago
(11-Oct-2024)
4/4 (100%)
$19.24 (25.40%)
323
Buy
$108
$-18.2 (-14.42%)
$106
3 months 17 days ago
(04-Oct-2024)
21/21 (100%)
$35.11 (48.17%)
244
Buy
$130
$3.8 (3.01%)
$130
4 months 1 days ago
(20-Sep-2024)
26/29 (89.66%)
$52.39 (67.50%)
497
Which stock is Ashwani Verma is most bullish on?
Which stock is Ashwani Verma is most reserved on?
What Year was the first public recommendation made by Ashwani Verma?
